Association of Frailty Index with Clinical Benign Prostatic Hyperplasia Progression and Serious Adverse Events: The MTOPS Trial

    December 2021 in “ Innovation in aging ”
    Sandra Shi, Brianne Olivieri‐Mui, Ellen P. McCarthy, Dae Hyun Kim
    Image of study
    TLDR Frailer men have a higher risk of worsening prostate problems and serious health events needing hospital care.
    In a study involving 3,047 men aged 50-89 years from the Medical Therapy of Prostatic Symptoms Study, researchers found that frailty is independently associated with a higher risk of clinical benign prostatic hyperplasia (BPH) progression and serious adverse events (SAE) requiring hospitalization. Participants were categorized based on a frailty index as fit, less fit, or frail. Over a mean follow-up of 4.5 years, the incidence rate of clinical BPH progression was 2.2 per 100 person-years (p-y) for fit men, 3.0 per 100 p-y for less fit men, and 4.1 per 100 p-y for frail men. Additionally, frail men randomized to combination therapy had a SAE incidence rate of 12.7 per 100 p-y compared to 3.4 per 100 p-y for fit men. The study suggests that treatment decisions for BPH in frail men should carefully weigh the benefits and risks.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 76 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Wtf have we been doing for the last 30 years

      in Treatment  526 upvotes 4 days ago
      Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

      community Why does finasteride stop working?

      in Finasteride/Dutasteride  26 upvotes 2 months ago
      Finasteride may seem less effective over time due to increased DHT sensitivity or aging, but it still suppresses DHT. Switching to dutasteride offers stronger DHT suppression but may increase estrogen levels.

      community My mum is mad annoying about Fin.

      in Chat  245 upvotes 7 months ago
      A 25-year-old man discusses his struggles with his mother's opposition to his use of Finasteride for hair loss treatment, despite it improving his condition and self-control after a hair transplant. He expresses frustration over her blaming the medication for various issues and the stress caused by her insistence to stop taking it.

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 1 year ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

    Related Research

    1 / 1 results